ArticleMediators of inflammation2006
Lymphocyte subpopulations in pulmonary tuberculosis patients.
Article in Mediators of inflammation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 45 citations in OpenAlex.
- Development and validation of a primary care-accessible risk prediction model for severe pulmonary TB.IJTLD open · 2026Article
- Pediatric pulmonary and extrapulmonary tuberculosis: immunological and diagnostic perspectives.BMC infectious diseases · 2026Article
- The clinical features and prognostic factors of miliary tuberculosis in a high tuberculosis burden area.Annals of medicine · 2024Article
- Possible Mechanisms of Lymphopenia in Severe Tuberculosis.Microorganisms · 2023Review
- The relationship between absolute counts of lymphocyte subsets and clinical features in patients with pulmonary tuberculosis.The clinical respiratory journal · 2022Article
- Sleep quality and its associated factors among patients with tuberculosis: A cross-sectional study.Frontiers in public health · 2022Article
- Adaptive immunity in different CT patterns of active tuberculosis and possible variability according to patients' geographic provenience.Frontiers in medicine · 2022Article
- Association between depression or anxiety symptoms and immune-inflammatory characteristics in in-patients with tuberculosis: A cross-sectional study.Frontiers in psychiatry · 2022Article
- Single-cell transcriptomics of blood reveals a natural killer cell subset depletion in tuberculosis.EBioMedicine · 2020Article
- T lymphocyte subpopulations and intestinal helminthes profile among tuberculosis patients co-infected with HIV before and after anti tubercular treatment at University of Gondar Hospital, Northwest Ethiopia.BMC infectious diseases · 2020Article
- The diagnostic accuracy of pericardial and urinary lipoarabinomannan (LAM) assays in patients with suspected tuberculous pericarditis.Scientific reports · 2016Article
- The CD4+/CD8+ Ratio in Pulmonary Tuberculosis: Systematic and Meta-Analysis Article.Iranian journal of public health · 2015Review
- Natural killer cells: a coherent model for their functional role in Mycobacterium tuberculosis infection.Journal of innate immunity · 2015Review
- Immunological markers and hematological parameters among newly diagnosed tuberculosis patients at Jimma University Specialized Hospital.Ethiopian journal of health sciences · 2014Article
- Can immune parameters be used as predictors to distinguish between pulmonary multidrug-resistant and drug-sensitive tuberculosis?Archives of medical science : AMS · 2010Article
- CD3, CD4, CD8, CD19 and CD16/CD56 positive cells in tuberculosis infection and disease: Peculiar features in children.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protection against Mycobacterium tuberculosis is based on cell-mediated immunity, most importantly involving CD4(+) and CD8(+) T-cell subsets. The aim of this study was to evaluate CD4(+) and CD8(+) T-cell profiles and CD19(+) and CD3(+)CD(16 + 56)(+) populations in patients with pulmonary tuberculosis. CD4(+) and CD8(+) T cells, B-lymphocytes, and natural killer (NK) cells were evaluated in 75 active (APTB) and 25 inactive (IPTB) pulmonary tuberculosis cases and 20 healthy subjects (HCs). The results were compared at different stages of antituberculosis treatment in the APTB patients and also according to X-ray findings in the newly diagnosed APTB patients. The percentages of CD4(+) T cells were significantly lower (P < .01) and those of CD3(+)CD(16+56)(+) cells were significantly higher (P < .01) in APTB patients than in HCs. CD8(+) T cells were significantly decreased (P < .05), and CD3(-)CD(16+56)(+) cells were significantly increased (P < .01), in IPTB patients compared to HCs. The percentages of CD4(+), CD8(+), CD3(-)CD19(+), and CD3(-)CD(16+56)(+) cells showed no differences at different times of the antituberculosis regimen, and different stages of newly diagnosed APTB patients. APTB patients have a reduced percentage of circulating CD4(+) T cells and an increased percentage of NK cells compared with healthy individuals. These cells could play important roles in the immune response to M tuberculosis infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.